antiquity
03-13-2002, 12:30 AM
NeoTherapeutics to Host Conference Call to Discuss Recent Financing Developments and the Timing of the Release of Data From Its Pivotal Alzheimer's Disease Clinical Trial -- Company will also review fourth quarter 2001 financial results and provide an update on its new series of anti-psychotic compounds Call set for Thursday, March 14, 2002 at 10:30 a.m. Eastern time
IRVINE, Calif., Mar 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) will hold a conference call on Thursday, March 14th at 10:30 a.m. Eastern time, 7:30 a.m. Pacific time, to discuss recent financing developments and the status of the release of data from the Company's ongoing pivotal Alzheimer's disease clinical trial. Management will also review financial results for the fourth quarter and year ended December 2001, and provide an update on the Company's exciting new series of anti- psychotic compounds.
Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer; Rajesh Shrotriya, M.D., President and Chief Operating Officer; and, Samuel Gulko, Senior Vice President, Finance and Chief Financial Officer, will host the call.
To access the call please dial 888-552-7850 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on the Company's website at www.neot.com (http://www.neot.com).
NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com (http://www.neot.com).
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
(508) 647-9782, ext. 15
INVESTOR RELATIONS
John McManus
NeoTherapeutics, Inc.
(949) 788-6700, ext. 247
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44256851
SOURCE NeoTherapeutics, Inc.
CONTACT: MEDIA RELATIONS: Jon Siegal of Ronald Trahan Associates (RTA)
Inc., +1-508- 647-9782, ext. 15; or INVESTOR RELATIONS: John McManus of
NeoTherapeutics, Inc., +1-949-788-6700, ext. 247
URL:
http://www.neot.com
IRVINE, Calif., Mar 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) will hold a conference call on Thursday, March 14th at 10:30 a.m. Eastern time, 7:30 a.m. Pacific time, to discuss recent financing developments and the status of the release of data from the Company's ongoing pivotal Alzheimer's disease clinical trial. Management will also review financial results for the fourth quarter and year ended December 2001, and provide an update on the Company's exciting new series of anti- psychotic compounds.
Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer; Rajesh Shrotriya, M.D., President and Chief Operating Officer; and, Samuel Gulko, Senior Vice President, Finance and Chief Financial Officer, will host the call.
To access the call please dial 888-552-7850 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on the Company's website at www.neot.com (http://www.neot.com).
NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com (http://www.neot.com).
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
(508) 647-9782, ext. 15
INVESTOR RELATIONS
John McManus
NeoTherapeutics, Inc.
(949) 788-6700, ext. 247
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44256851
SOURCE NeoTherapeutics, Inc.
CONTACT: MEDIA RELATIONS: Jon Siegal of Ronald Trahan Associates (RTA)
Inc., +1-508- 647-9782, ext. 15; or INVESTOR RELATIONS: John McManus of
NeoTherapeutics, Inc., +1-949-788-6700, ext. 247
URL:
http://www.neot.com